Navigation Links
Maxygen Announces Management Changes
Date:3/4/2008

REDWOOD CITY, Calif., March 4 /PRNewswire-FirstCall/ -- Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, today announced changes to its management team. Grant Yonehiro, Maxygen's senior vice president in charge of global business development and U.S. operations, has been appointed to the position of chief business officer. In addition, the company announced the pending departure of Michael Rabson, Maxygen's general counsel since 1999, to pursue another career opportunity. Maxygen's in-house legal team will be reorganized to assume Dr. Rabson's responsibilities.

Mr. Yonehiro joined Maxygen in May 2003 as vice president of business development; his role was later expanded to include responsibility for managing the company's U.S. operations. During his tenure at Maxygen, Mr. Yonehiro established business collaborations with Roche and Sanofi-Pasteur, and has driven contract relationships with third parties such as the Department of Defense and National Institutes of Health.

"Over the past several years Grant has landed some key partnerships and agreements for Maxygen, while also managing our U.S. operations," said Dr. Howard. "With our worldwide operations now consolidated here in Redwood City under Elliot Goldstein, our chief operating officer, Grant can now intensify business development activity, which is critical to our long-term success."

Upon Dr. Rabson's departure, Maxygen's in-house legal team will be reorganized to assume his responsibilities. Norman Kruse, Maxygen's vice president of intellectual property and chief patent counsel, will continue leading Maxygen's intellectual property team and will now be responsible for providing strategic intellectual property counsel for the company, reporting directly to the CEO. Dr. Kruse has been with Maxygen since March 1998. John Borkholder, who joined Maxygen in November 2005 as senior corporate counsel, has been promoted to chief corporate counsel and was appointed corporate secretary. Mr. Borkholder will continue to oversee the company's SEC and corporate governance compliance, and will take on an expanded corporate advisory role.

"I would like to acknowledge the significant contributions Michael Rabson has made to our company over the years," said Dr. Howard. "Under Michael's leadership, Maxygen has built an IP estate that is recognized as one of the best in the biotechnology industry(1) and a legal team with the expertise to grow and maintain the value of our products."

About Maxygen

Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. The company's lead program, MAXY-G34, is designed to be an improved version of long-acting G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in Maxygen's pipeline are a new Factor VIIa product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of rheumatoid arthritis. Maxygen uses its proprietary DNA shuffling technology and extensive protein modification expertise to pursue the creation of biosuperior proteins. http://www.maxygen.com

(1) The Patent Scorecard(TM), http://www.patentboard.com


'/>"/>
SOURCE Maxygen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Maxygen Reports Fourth Quarter and Year End 2007 Financial Results
2. Maxygen to Present at the Roth 20th Annual OC Growth Stock Conference
3. Maxygen to Present at the Stanford Group Company 13th Annual Healthcare Conference
4. Maxygen to Present at the JPMorgan 26th Annual Healthcare Conference
5. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
6. Maxygen Reports Third Quarter 2007 Financial Results
7. Maxygen Announces Upcoming Webcasts at Investor Conferences
8. Maxygen Third Quarter 2007 Financial Results Conference Call Notice
9. Maxygen Announces Hold on MAXY-alpha Development Program
10. Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility
11. Exanet Announces ExaStore 2008 Clustered NAS System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc announced ... client demand KbioBox developed a sophisticated “3 click” gene dditing off target analysis ... KBioBox’s new website, https://www.kbiobox.com/ and powered by the company’s proprietary ...
(Date:12/8/2016)... Dec. 8, 2016  Soligenix, Inc. (OTCQB: SNGX) ... focused on developing and commercializing products to treat ... need, announced today the long-term follow-up data from ... a first-in-class Innate Defense Regulator (IDR), in the ... neck cancer patients undergoing chemoradiation therapy (CRT).  The ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/7/2016)... ... 2016 , ... A new study published in the just-published ... advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute for tissue ... sampling may improve the value of a blood-based test.” The study was conducted ...
Breaking Biology Technology:
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today introduced ... and their trainers non-invasively measure hemoglobin, Oxygen ... Rate, and Respiration Rate in approximately 30 seconds. Smaller ... easy and immediate access to key data about their ... a training regimen. Hemoglobin carries oxygen ...
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/17/2016)... OF INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it has ... using NVMe storage servers in organizations that require high-performance scale-out plus high speed data transfer storage ... ... ... Setting up ...
Breaking Biology News(10 mins):